Results 21 to 30 of about 14,990 (249)

Biologic drugs in treating allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a systematic review

European Respiratory Review, 2022
Background Aspergillus fumigatus is a common saprophytic fungus causing allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis (CF).
S. Manti, Alessandro Giallongo, G. Parisi, M. Papale, E. Mulé, Donatella Aloisio, N. Rotolo, S. Leonardi   +7 more
semanticscholar   +1 more source

Antifungal Susceptibility Profile of Aspergillus Strains Isolated From the Lower Respiratory Tract in Eastern Indian Patients: A Hospital-Based Study. [PDF]

Microbiologyopen
Treatment for chronic to invasive pulmonary aspergillosis typically involves azole antifungal drugs, although studies have shown varying minimum inhibitory concentrations (MIC) for these medications, with a growing concern over voriconazole resistance.
Nikhil A, Choudhury S, Bhatia M, Tiwari AK, Srivastava R, Prasad A, Tilak R, Gupta MK, Narayan RJ.   +8 more
europepmc   +2 more sources

Allergic bronchopulmonary aspergillosis: diagnostic and treatment challenges [PDF]

, 2016
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder, occurring mostly in asthmatic and cystic fibrosis patients, caused by an abnormal T-helper 2 lymphocyte response of the host to Aspergillus fumigatus antigens.
CINICOLA, BIANCA LAURA, DUSE, MARZIA, Laitano, Rossella, LEONARDI, LUCIA   +3 more
core   +1 more source

A unique case of hydropneumothorax in allergic bronchopulmonary aspergillosis

Medical Mycology Case Reports, 2019
Allergic bronchopulmonary aspergillosis (ABPA) is an immunologically mediated disease characterized by a hypersensitivity reaction to fungal colonization by Aspergillus.
Tejas Suri, Nayani Makkar, Animesh Ray, Rita Sood   +3 more
doaj   +1 more source

Prospective evaluation of a new Aspergillus IgG EIA kit for the diagnosis of chronic and allergic pulmonary aspergillosis [PDF]

, 2016
International ...
Bailly, S., Brenier-Pinchart, M. P., Camara, B., Cornet, M., Dumollard, C., Gangneux, Jean-Pierre, Grenouillet, F., Pelloux, H., Perriot, S., Persat, F., Pinel, C., Saint-Raymond, C., Valot, S.   +12 more
core   +4 more sources

Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial

European Respiratory Journal, 2021
Background In allergic bronchopulmonary aspergillosis (ABPA), prolonged nebulised antifungal treatment may be a strategy for maintaining remission. Methods We performed a randomised, single-blind, clinical trial in 30 centres.
C. Godet, F. Couturaud, S. Marchand-Adam, C. Pison, F. Gagnadoux, E. Blanchard, C. Taillé, B. Philippe, S. Hirschi, C. Andrejak, A. Bourdin, C. Chenivesse, S. Dominique, L. Bassinet, M. Murris‐Espin, F. Rivière, G. Garcia, D. Caillaud, F. Blanc, F. Goupil, Anne Bergeron, A. Gondouin, J. Frat, T. Flament, B. Camara, P. Priou, A. Brun, F. Laurent, S. Ragot, J. Cadranel   +29 more
semanticscholar   +1 more source

Bronchiectasis in India:results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry [PDF]

, 2019
BACKGROUND: Bronchiectasis is a common but neglected chronic lung disease. Most epidemiological data are limited to cohorts from Europe and the USA, with few data from low-income and middle-income countries.
Aleemuddin, Naveed M., Aliberti, Stefano, Anantharaj, Suresh, Baburao, Archana, Batra, Sakshi, Chalmers, James D., Chandrashekaria, Sagar, Chauhan, Nishant Kumar, Crichton, Megan L., D'Souza, George, Das, Akanksha, De Soyza, Anthony, Dhar, Raja, Dimakou, Katerina, Dutt, Naveen, Gami, Samir, Garg, Himanshu, Ghewade, Babaji, Goeminne, Pieter C., Gulecha, Nayan Sri, Hasan, Ashfaq, Jajodia, Nikita, Jayadevappa, Gayathri Devi H., Jayaraj, Biiligere Siddaiah, Jindal, Aditya, Jindal, Surinder Kumar, Karmakar, Saurabh, Khanna, Arjun, Kungwani, Rahul, Limaye, Sneha, Mahesh, Padukudru Anand, Mangala, Anshul, McDonnell, Melissa J., Mishra, Aditi, Mohan, Murali, Nair, Girija, Padmanabhan, Arjun, Polverino, Eva, Prajapat, Deepak, Prasad, Rajendra, Rajagopala, Srinivas, Ramanathan, Ramanathan Palaniappan, Rutherford, Robert, Saha, Kaushik, Salvi, Sundeep, Sarmah, Kripesh Ranjan, Sawhney, Honney, Sawhney, Mehneet, Shah, Arpan, Shah, Arti, Shah, Palak, Sharma, Shubham, Shteinberg, Michal, Singh, Sheetu, Singh, Virendra, Singhal, Ashutosh, Swarnakar, Rajesh, Talwar, Deepak, Torres, Antoni, Tripathi, Surya Kant, Trivedi, Sonali, Vasudev, Preethi, Venugopal, Kummannoor, Vyas, Sunil   +63 more
core   +5 more sources

Successful Treatment of Mepolizumab- and Prednisolone-resistant Allergic Bronchopulmonary Aspergillosis with Dupilumab

Internal medicine, 2021
A 45-year-old man with allergic bronchopulmonary aspergillosis (ABPA) was treated with oral prednisolone (PSL) (30 mg/day), inhaled corticosteroids, and long-acting beta2-agonists.
Sunao Mikura, T. Saraya, Yuki Yoshida, Miku Oda, M. Ishida, Kojiro Honda, K. Nakamoto, Masaki Tamura, S. Takata, H. Shimoyamada, M. Fujiwara, H. Ishii   +11 more
semanticscholar   +1 more source

Aspergillus Serology Predicts Relapse in Chronic Pulmonary Aspergillosis: Implications for Personalised Follow‐Up Strategies [PDF]

Mycoses
ABSTRACT Introduction Relapses occur in up to 40% of patients after prolonged courses of antifungal treatment for chronic pulmonary aspergillosis (CPA). The factors predisposing to relapse remain poorly defined. Methods We conducted a retrospective study of adults treated for ≥ 6 months with oral azoles for CPA.
Choyce A, Colombo S, Cyriac C, Alasfour A, Ng W, Amphlett L, Kosmidis C.   +6 more
europepmc   +2 more sources

Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis

Oxford Medical Case Reports, 2021
Allergic bronchopulmonary aspergillosis (ABPA) is a disease characterized by severe disability with recurrent wheezing and shortness of breath. The current recommended therapy is daily oral corticosteroids +/− oral antifungal therapy.
Muhammad Ali, O'Neil Green
semanticscholar   +1 more source